CN116209755A - 可编程核酸酶和使用方法 - Google Patents

可编程核酸酶和使用方法 Download PDF

Info

Publication number
CN116209755A
CN116209755A CN202180056722.7A CN202180056722A CN116209755A CN 116209755 A CN116209755 A CN 116209755A CN 202180056722 A CN202180056722 A CN 202180056722A CN 116209755 A CN116209755 A CN 116209755A
Authority
CN
China
Prior art keywords
programmable
nuclease
nucleic acid
casφ
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056722.7A
Other languages
English (en)
Chinese (zh)
Inventor
卢卡斯·本杰明·哈林顿
威廉·道格拉斯·赖特
刘佩琪
本杰明·朱利叶斯·劳奇
维普特拉·贾亚·哈托诺
布里奇特·安·潘恩·麦凯
达努塔·萨斯特雷·菲普斯
郑宇轩
尼雷亚·桑维森斯
肖恩·陈
大卫·佩兹-埃斯皮诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mammoth Biosciences Inc
Original Assignee
Mammoth Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mammoth Biosciences Inc filed Critical Mammoth Biosciences Inc
Publication of CN116209755A publication Critical patent/CN116209755A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180056722.7A 2020-06-03 2021-06-03 可编程核酸酶和使用方法 Pending CN116209755A (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063034346P 2020-06-03 2020-06-03
US63/034,346 2020-06-03
US202063037535P 2020-06-10 2020-06-10
US63/037,535 2020-06-10
US202063040998P 2020-06-18 2020-06-18
US63/040,998 2020-06-18
US202063092481P 2020-10-15 2020-10-15
US63/092,481 2020-10-15
US202063116083P 2020-11-19 2020-11-19
US63/116,083 2020-11-19
US202063124676P 2020-12-11 2020-12-11
US63/124,676 2020-12-11
US202163156883P 2021-03-04 2021-03-04
US63/156,883 2021-03-04
US202163178472P 2021-04-22 2021-04-22
US63/178,472 2021-04-22
PCT/US2021/035781 WO2021247924A1 (en) 2020-06-03 2021-06-03 Programmable nucleases and methods of use

Publications (1)

Publication Number Publication Date
CN116209755A true CN116209755A (zh) 2023-06-02

Family

ID=78829953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056722.7A Pending CN116209755A (zh) 2020-06-03 2021-06-03 可编程核酸酶和使用方法

Country Status (7)

Country Link
US (3) US20230357735A1 (https=)
EP (1) EP4162052A4 (https=)
JP (1) JP2023529151A (https=)
CN (1) CN116209755A (https=)
AU (1) AU2021282578A1 (https=)
CA (1) CA3178670A1 (https=)
WO (1) WO2021247924A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116844639A (zh) * 2023-06-14 2023-10-03 上海诚明融鑫科技有限公司 一种具有自适应学习控制能力的人类mtDNA快速比对方法及装置
CN119351374A (zh) * 2024-12-23 2025-01-24 内蒙古大学 工程化改造超紧凑型CRISPR/Cas12j-8及其应用
CN120330238A (zh) * 2025-04-10 2025-07-18 北京林业大学 一种ect2基因在调控杨树次生木质部发育中的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
US20240026351A1 (en) * 2020-10-30 2024-01-25 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
WO2023173110A1 (en) * 2022-03-11 2023-09-14 Epicrispr Biotechnologies, Inc. Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
WO2023220654A2 (en) * 2022-05-10 2023-11-16 Mammoth Biosciences, Inc. Effector protein compositions and methods of use thereof
WO2023220649A2 (en) * 2022-05-10 2023-11-16 Mammoth Biosciences, Inc. Effector protein compositions and methods of use thereof
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
WO2024047587A1 (en) * 2022-08-31 2024-03-07 Regel Therapeutics, Inc. Cas-phi compositions and methods of use
WO2024073114A1 (en) * 2022-09-30 2024-04-04 Vedabio, Inc. Delivery of therapeutics in vivo via a crispr-based cascade system
WO2024091958A1 (en) * 2022-10-25 2024-05-02 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods for the modification of serpina1
WO2024107665A1 (en) * 2022-11-14 2024-05-23 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods of use thereof
WO2024127370A1 (en) * 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
EP4637841A1 (en) * 2022-12-22 2025-10-29 Mammoth Biosciences, Inc. Compositions and methods for modifying dux4
EP4673550A2 (en) * 2023-02-27 2026-01-07 Mammoth Biosciences, Inc. Compositions and methods for the modification and regulation of liver gene expression
AU2024236558A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024238321A1 (en) * 2023-05-12 2024-11-21 Mammoth Biosciences, Inc. Compositions and methods for targeted epigenetic modification
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025050015A1 (en) * 2023-09-01 2025-03-06 Script Biosciences, Inc. Compositions and methods for targeted modification of msh3
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170175128A1 (en) * 2014-04-18 2017-06-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20190093090A1 (en) * 2015-12-29 2019-03-28 Monsanto Technology Llc Novel CRISPR-Associated Transposases and Uses Thereof
WO2020028729A1 (en) * 2018-08-01 2020-02-06 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US20110275135A1 (en) * 2010-05-05 2011-11-10 Battelle Energy Alliance, Llc Genetic elements, proteins, and associated methods including application of additional genetic information to gram (+) thermoacidophiles
WO2012164565A1 (en) * 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3445853A1 (en) * 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
MX2021010559A (es) * 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170175128A1 (en) * 2014-04-18 2017-06-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20190093090A1 (en) * 2015-12-29 2019-03-28 Monsanto Technology Llc Novel CRISPR-Associated Transposases and Uses Thereof
WO2020028729A1 (en) * 2018-08-01 2020-02-06 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BASEM AL-SHAYEB: "Clades of huge phages from across Earth\'s ecosystems", NATURE., vol. 578, no. 7795, 12 February 2020 (2020-02-12), pages 425 - 431 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116844639A (zh) * 2023-06-14 2023-10-03 上海诚明融鑫科技有限公司 一种具有自适应学习控制能力的人类mtDNA快速比对方法及装置
CN119351374A (zh) * 2024-12-23 2025-01-24 内蒙古大学 工程化改造超紧凑型CRISPR/Cas12j-8及其应用
CN119351374B (zh) * 2024-12-23 2025-03-25 内蒙古大学 工程化改造超紧凑型CRISPR/Cas12j-8及其应用
CN120330238A (zh) * 2025-04-10 2025-07-18 北京林业大学 一种ect2基因在调控杨树次生木质部发育中的应用

Also Published As

Publication number Publication date
WO2021247924A1 (en) 2021-12-09
AU2021282578A1 (en) 2023-02-02
EP4162052A4 (en) 2024-07-10
US20230167454A1 (en) 2023-06-01
EP4162052A1 (en) 2023-04-12
US20230357735A1 (en) 2023-11-09
JP2023529151A (ja) 2023-07-07
US20250066797A1 (en) 2025-02-27
CA3178670A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CN116209755A (zh) 可编程核酸酶和使用方法
US20220033858A1 (en) Crispr oligoncleotides and gene editing
EP4491723A1 (en) Cytosine deaminase and use thereof in base editing
JP7093728B2 (ja) 化学的に修飾されたガイドrnaを使用する高特異性ゲノム編集
US11814620B2 (en) Effector proteins and methods of use
CN119998447A (zh) 新型腺嘌呤脱氨酶变体及使用其进行碱基编辑的方法
US20240327810A1 (en) Effector proteins and methods of use
US20240191281A1 (en) Programmable nucleases and methods of use
US12077775B2 (en) Effector proteins and methods of use
US20230332218A1 (en) Casy programmable nucleases and rna component systems
WO2022221581A1 (en) Programmable nucleases and methods of use
US20230348877A1 (en) Base editing enzymes
KR20240055098A (ko) 화학적 변형을 갖는 가이드 rna를 사용하는 방법
US20240191280A1 (en) Enhanced guide nucleic acids and methods of use
US20250043313A1 (en) Cas9 variants with improved specificity
US20230257739A1 (en) Effector proteins and methods of use
WO2024220715A2 (en) Effector proteins and uses thereof
EP4522737A2 (en) Engineered cas-phi proteins and uses thereof
WO2024192211A2 (en) Effector proteins and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination